IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. PCT/EP2004/002350 International Filing Date March 8, 2004 Priority Date(s) Claimed April 3, 2003 Applicant(s) (DO/EO/US) Christos TSAKLAKIDIS et al. Title: CARBONYL COMPOUNDS INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees \boxtimes Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); \boxtimes within three months of the actual filing date of the national phase of a PCT application; OR before the mailing of a first substantive office action (including after filing of an RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of: a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

a notice of allowance under 37 C.F.R. § 1.311; and

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a	notice of allowance under 37 C.F.R. § 1.311;
	AND:	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	<u>Materia</u>	<u>ls</u>	
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	-	s of materials listed but not attached were cited in an international search dated November 12, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).

Non-En	glish Language Refe	<u>rences</u>
[nguage search report or equivalent paper from a foreign patent ded indicating the relevance of the cited reference(s).
		guage search report from a foreign patent office is provided, and are translated substantively below:
	Y = docum	
	O = non-w	ent defining the general state of the art ritten disclosure lated document
		ent cited to understand the theory or principle underlying the ion
	and w	document which has the benefit of a date earlier than the filing date nich was published only on or after this filing date
		n the application
		or another reason ation of member of same patent family
	Translation o	other relevant information on foreign search report
	"Verbindunge examples, and means colum means examp table, and "Ta in the applica	report, "Seite" means page, "Seiten" means pages, in der Formel" means Figure of formula, "Beispele" means la "das ganze Dokument" means the entire document, "Spalte" in, "Zeile" means line, "Abbildungen" means claims, "Anspruch" le, "Zusammenfassung" means summary, and "Tabelle" means bellen" means tables "in der Anmeldung erwaehnt" means cited tion, "Schema" means scheme, "und" means and, "Absatz" "Abildung" means figure.
Other In	<u>nformation</u>	
Paymen	nt of Fees Due (If An	v):
		covering the fee identified above is attached.
	Please charge to Den	osit Account No. 13-3402 \$ for the fee identified above.

JC12 Rec'd PCT/PTC 03 OCT 2005

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2723

Date: October 3, 2005

AJZ:aap

iK:\Merck\2000 - 2999\2723\Information Disclosure Statement.doc

10/551557 JC12 Rec'd PCT/PTC 03 OCT 2005

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	Unassigned	
INFO	RMATION	DIS	CLOSURE	Filing Date	October 3, 2005	
STAT	TEMENT B	Y AI	PPLICANT	First Named Inventor	Christos TSAKLAKIDIS et al.	
				Group Art Unit	Unassigned	
	(use as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	MERCK-2723	

			U.	S. PATENT DOCUMENTS	
Examiner		U.S. Patent Docume		Name of Patentee or Applicant	Date of Publication of Cited Document
Initials *	Cite No.1	Number	(if known)	of Cited Document	MM-DD-YYYY
	1	2002002183			January 3, 2002
-	2	6673817			January 6, 2004
	3	2002055469			May 9, 2002
	4	2004097550			May 20, 2004
	5	2004010017			January 15, 2004
	6	2004087582		-	May 6, 2004
	7	2004038858			February 26, 2004
-	8	5705487			January 6, 1998
	9	6635657			October 21, 2003
	10	2004097547			May 20, 2004
	11	2003162787			August 28, 2003
	12	5705487			January 6, 1998

	_			FO	REIGN PATENT DOCUM	ENTS		
Examiner Initials*	Cite No.¹	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴	
	13	wo	0164642		Cor Therapeutics	September 7, 2001		Equv to cite 1
	14	wo	0071516		Cor Therapeutics Inc.	November 30, 2000		Equv to cite 2
	15	wo	0222575		Genentech Inc	March 21, 2002		Equv to cite 3
	16	wo	02074735		Merck Patent GmbH	September 26, 2002		Equv to cite 4
	17	wo	0214308		Lilly Co Eli	February 21, 2002		Equv to cite 5
	18	wo	02057236		Merck Patent GmbH	July 25, 2002		Equv to cite 6

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

10/551557,

JC12 Rec'd PCT/FTC 03 OCT 2005

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	Unassigned	
INFO	RMATION	DISC	LOSURE	Filing Date	October 3, 2005	
STAT	EMENT B	Y AP	PLICANT	First Named Inventor	Christos TSAKLAKIDIS et al.	
				Group Art Unit	Unassigned	
_ ((use as many she	ets as n	ecessary)	Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	MERCK-2723	

U.S. PATENT DOCUMENTS								
		U.S. Patent Doc			Date of Publication of Cited Document			
Examiner Initials *	Cite No.1	Number	Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY			
					· · · · · · · · · · · · · · · · · · ·			
		 -						
								
					-W			

				FOF	REIGN PATENT DOCUME	NTS	0	
Examiner	Cite No.1	Office ³	Foreign Patent Docum	ent Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т•
micaio	19	wo	0248099		Merck Patent GmbH	June 20, 2002	1	Equv to cite 7
	20	wo	9523609		Lilly Co Eli	September 8, 1995		Equv to cite 12
	21	wo	0039118		Eli Lilly & Co	July 6, 2000		Equv to cite 9
	22	wo	02083624		Schering Corp/Pharmacopeia Inc	October 24, 2002		Equv to cite 10
	23	GB	1503244		Mitsubishi Chem Ind	March 8, 1978		
	24	wo	03045912		Warner Lambert Co LLT	June 5, 2003		Equv to cite 11
	25	wo	03050088		Eli Lilly & Co	June 19, 2003		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

10/551557

JC12 Rec'd PCT/PTC 03 OCT 2005

Please type	a plus	sign (+)	inside this	\rightarrow	+
, p.	- F				

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	r form 1449A/PTO	•		Complete if Known		
	A A TION	D 10		Application Number	Unassigned	
			CLOSURE	Filing Date	October 3, 2005	
STATE	EMENT B	Y AI	PPLICANT	First Named Inventor	Christos TSAKLAKIDIS et al.	
				Group Art Unit	Unassigned	
(u	se as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number MERCK-2723		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	26	Database Beilsten Beilstein Institute for Organic Chemistry, Frankfurt-Main, De; June 27, 1988 XP002282645.	
	27	Database Beilstein Beilstein Institute fro Organic Chemistry, Frankfurt-Main, DE June 27, 1988 XP002282646	
	28	Database Beilstein Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE March 19, 1991, XP002282647.	
	29	Database Beilstein Beilstein Insitute for Organic Chemistry, Frankfurt-Main, DE August 9, 1996, XP002283422	
	_		
	-		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.